NeuroMetrix
Medical device company focused on the diagnosis and treatment of the neurological complications of diabetes.
Launch date
Employees
Market cap
€7.5m
Enterprise valuation
(€7m) (Public information from Sep 2024)
Share price
$3.82 NURO
Waltham Massachusetts (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 17.1m | 16.1m | 9.3m | 7.4m | 8.3m | 8.3m | 5.9m |
| % growth | - | (6 %) | (42 %) | (20 %) | 12 % | - | (29 %) |
| EBITDA | (12.8m) | (12.1m) | (11.5m) | (2.1m) | (2.3m) | (4.7m) | (7.1m) |
| % EBITDA margin | (75 %) | (75 %) | (124 %) | (28 %) | (28 %) | (57 %) | (120 %) |
| Profit | (12.9m) | <1m | (3.8m) | (2.1m) | (2.3m) | (4.4m) | (6.5m) |
| % profit margin | (75 %) | - | (41 %) | (28 %) | (28 %) | (53 %) | (111 %) |
| EV / revenue | - | -0.1x | 0.3x | 1.1x | 1.4x | -1.1x | -2.4x |
| EV / EBITDA | - | 0.1x | -0.2x | -3.7x | -5.0x | 2.0x | 2.0x |
| R&D budget | 3.5m | 5.1m | 3.1m | 2.4m | 2.6m | 3.2m | 2.8m |
| R&D % of revenue | 20 % | 32 % | 33 % | 32 % | 31 % | 39 % | 47 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $14.7m | Post IPO Equity | |
| N/A | $13.8m | Post IPO Equity | |
| N/A | $21.0m | Post IPO Equity | |
| N/A | $7.0m | Post IPO Equity | |
| N/A | $3.5m | Post IPO Equity | |
| Total Funding | €12.7m | ||
Related Content
Recent News about NeuroMetrix
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by NeuroMetrix
Edit
ACQUISITION by NeuroMetrix Dec 2007